NASDAQ:ACON Aclarion Q1 2025 Earnings Report $6.99 +0.04 (+0.58%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$7.03 +0.04 (+0.57%) As of 08/1/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Aclarion EPS ResultsActual EPS-$9.32Consensus EPS -$1,447.20Beat/MissBeat by +$1,437.88One Year Ago EPSN/AAclarion Revenue ResultsActual Revenue$0.02 millionExpected Revenue$0.02 millionBeat/MissMissed by -$1.00 thousandYoY Revenue GrowthN/AAclarion Announcement DetailsQuarterQ1 2025Date5/15/2025TimeBefore Market OpensConference Call DateWednesday, May 14, 2025Conference Call Time6:00PM ETUpcoming EarningsAclarion's Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Tuesday, August 12, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Aclarion Earnings HeadlinesAclarion, Inc. Adjourns Annual Meeting to Solicit VotesJuly 30 at 11:25 AM | theglobeandmail.comAclarion, Inc. Announces Adjournment of Annual Meeting of StockholdersJuly 7, 2025 | globenewswire.comThis Crypto Is Set to Explode in JanuaryThis Could Be the Most Important Crypto Law in History While the world celebrates Bitcoin becoming 2025’s top-performing asset, smart hedge funds are accumulating elsewhere. During the upcoming Crypto Hedge Fund Summit, you'll discover exactly which coins they’ve loaded up on before this historic vote.August 2 at 2:00 AM | Crypto 101 Media (Ad)ACON - Aclarion Inc Ordinary Shares Chart - MorningstarJuly 4, 2025 | morningstar.comMAclarion Enrolls First Patient In CLARITY Trial Evaluating Nociscan In Spine Surgery - NasdaqJune 27, 2025 | nasdaq.comFirst Patient Enrolled in Aclarion's Groundbreaking CLARITY TrialJune 25, 2025 | globenewswire.comSee More Aclarion Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aclarion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclarion and other key companies, straight to your email. Email Address About AclarionAclarion (NASDAQ:ACON), a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.View Aclarion ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon's Earnings: What Comes Next and How to Play ItApple Stock: Big Earnings, Small Move—Time to Buy?Microsoft Blasts Past Earnings—What’s Next for MSFT?Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic?Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?RCL Stock Sinks After Earnings—Is a Buying Opportunity Ahead?Amazon's Pre-Earnings Setup Is Almost Too Clean—Red Flag? Upcoming Earnings Palantir Technologies (8/4/2025)Vertex Pharmaceuticals (8/4/2025)Axon Enterprise (8/4/2025)MercadoLibre (8/4/2025)Williams Companies (8/4/2025)ONEOK (8/4/2025)Simon Property Group (8/4/2025)Advanced Micro Devices (8/5/2025)Marriott International (8/5/2025)Amgen (8/5/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.